EUVIMEDEUVIMED entdecken
Crossref

Autologous hematopoietic stem cell transplantation for non-AL amyloidosis monoclonal gammopathy of renal significance

Mengnan Liu, Liang Zhao, Jinzhou Guo, Wencui Chen, Xiaomei Wu, Weiwei Xu, Xianghua Huang iD

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Mengnan Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Paraproteinemias, Kidney Diseases, Amyloidosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Research and Development Plan Project of Jiangsu Province-Social Development Projects, Key Research and Development Plan Project of Jiangsu Province—Social Development Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment strategy for non-immunoglobulin light chain (AL) amyloidosis monoclonal gammopathy of renal significance (MGRS) remains unstandardized. Autologous hematopoietic stem cell transplantation (ASCT) has shown favorable results in a limited number of studies.

Methods

This single-center, retrospective case-control study included non-AL amyloidosis MGRS patients diagnosed between February 2012 and July 2024; these patients were divided into the ASCT group and non-ASCT group. Baseline characteristics, ASCT characteristics and complications, treatment responses, survival outcomes, and risk factors for progression-free survival (PFS) were analyzed.

Results

A total of 53 patients with non-AL amyloidosis MGRS were enrolled in this study, comprising 23 patients who received ASCT and 30 patients who did not receive ASCT. The baseline characteristics were comparable between the ASCT and non-ASCT groups, with exceptions of serum albumin and C3 levels. The median overall survival (OS) and renal survival were not reached in either group. The median PFS was significantly longer in the ASCT group compared to the non-ASCT group (58.4 vs 16.4 months, P = .004). The overall response rate (ORR) and deep response rates of the ASCT group were higher than those of the non-ASCT group, both in hematological and renal responses. In the ASCT group, 18 patients (78.3%) achieved a hematological very good partial response (VGPR) or better, and 21 patients (91.3%) achieved a renal partial response or better after transplantation. Moreover, the ASCT group exhibited higher long-term cumulative incidences of OS and renal survival. The toxicity of ASCT was manageable, and no transplantation-related deaths occurred. There was no statistically significant difference in the median PFS between monoclonal immunoglobulin deposition disease and light chain proximal tubulopathy (P = .539). High serum albumin level at diagnosis, and hematological response ≥VGPR after ASCT were protective factors of PFS.

Conclusions

This study confirmed that ASCT was an effective and safe treatment for patients with non-AL amyloidosis MGRS, thereby offering long-term hematological remission and survival benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationParaproteinemiasKidney DiseasesAmyloidosisHumansMaleFemaleRetrospective StudiesMiddle AgedTransplantation, AutologousCase-Control StudiesFollow-Up StudiesPrognosisSurvival RateAdultAged

Stichwörter der Autor:innen

autologous hematopoietic stem cell transplantationefficacy and safetynon-AL amyloidosis MGRS

Autor:innen und Institutionen

  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

ORCID-Profile: Xianghua Huang

Förderung

  • National Natural Science Foundation of China
  • Key Research and Development Plan Project of Jiangsu Province-Social Development Projects
  • Key Research and Development Plan Project of Jiangsu Province—Social Development Projects

Zitieren

APA

Liu, M., Zhao, L., Guo, J., Chen, W., Wu, X., Xu, W., & Huang, X. (2025). Autologous hematopoietic stem cell transplantation for non-AL amyloidosis monoclonal gammopathy of renal significance. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf036

Vancouver

Liu M, Zhao L, Guo J, Chen W, Wu X, Xu W, et al. Autologous hematopoietic stem cell transplantation for non-AL amyloidosis monoclonal gammopathy of renal significance. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf036

BibTeX
@article{Liu2025,
  author = {Liu, Mengnan and Zhao, Liang and Guo, Jinzhou and Chen, Wencui and Wu, Xiaomei and Xu, Weiwei and Huang, Xianghua},
  title = {Autologous hematopoietic stem cell transplantation for non-AL amyloidosis monoclonal gammopathy of renal significance},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf036}
}
Kostenlos starten →